Biogen Chief Sees Biosimilars as ‘Meaningful Revenue Stream’
This article is for subscribers only.
Biogen Idec Inc., the world’s largest maker of multiple sclerosis drugs, plans to expand into biogenerics, Chief Executive Officer George Scangos said today.
“Biosimilars will have a major role to play in health care as we go forward,” Scangos said in an interview at the J.P. Morgan Healthcare Conference in San Francisco. “It’s clear there will be pressure on prices. Biosimilars are a way to get what presumably would be high-quality drugs to patients at a lower cost.”